Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02662842 · ClinicalTrials.gov registry record
BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims Study
A clinical trial, sponsored by Becton, Dickinson and Company.
- Completed
- Registry status
- 75
- Enrollment target
NCT02662842 is a clinical trial that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 75 participants.
The verdict
NCT02662842 has completed, sponsored by Becton, Dickinson and Company.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
Study Summary
Continuous Subcutaneous Insulin Infusion (CSII) via insulin pump therapy has been shown to improve quality of life and glucose control in many patients with diabetes opting for this treatment modality. Despite significant innovation and advancement in pump technology, insulin infusion sets have been an area where innovation has been significantly lacking with no clinical studies performed prior to product launches. BD has developed a subcutaneous infusion set with FlowSmart™ Technology designed to address patient comfort, insulin delivery and flow interruptions. According to preliminary animal and clinical studies, this technology results in lower infusion pressure indicating more consistent insulin delivery. The FlowSmart infusion set has been previously tested in prototype form with healthy non-diabetic subjects with the sets inserted by nurses, and with CSII-using patients who self-inserted the FlowSmart infusion set in a clinical research setting. The purpose of this study is to determine if insulin pump users prefer using the BD FlowSmart infusion set compared to their current set with respect to insertion pain and wear comfort.
Interventions
- DEVICE FlowSmart Infusion Set
- DEVICE Current Infusion Set
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02662842
The ClinicalTrials.gov registry entry for NCT02662842 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Becton, Dickinson and Company, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FlowSmart Infusion Set is the first listed.
NCT02662842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02662842 about?
NCT02662842 is a clinical study titled "BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims Study". Continuous Subcutaneous Insulin Infusion (CSII) via insulin pump therapy has been shown to improve quality of life and glucose control in many patients with diabetes opting for this treatment modality. Despite significant innovation and advancement in pump technology, insulin infusion sets have been...
What is the current status of trial NCT02662842?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2016-01. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02662842?
The interventions under investigation include: FlowSmart Infusion Set (DEVICE), Current Infusion Set (DEVICE).
Who is sponsoring clinical trial NCT02662842?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.